Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (6578)	7/26/2009 12:08:29 PM
From: Biotech Jim	1 Recommendation Respond to of 7143

Allostery as a concept has been around since the days of Jacob, Monod and Changeaux, if not earlier. Based on what I have seen, drug companies have been going after allosteric modulators for at least the past 10 years. Some have been later to the party than others, but the current era of whole cell and isolated receptor preparation functional assays was enacted since those types of screens picked up distinct small molecules that acted either as ligand site modulators as allosteric agents. As to side effects, one always has to be aware of mechanism-based side effects and non-mechanism based side effects. Yes, allostery may get around some of the mechanism-based side effects. So, the article makes it appear so much simpler and cleaner than reality. FWIW. BJ